FilingReader Intelligence
JCR Pharmaceuticals posts 546m yen loss despite sales growth
July 30, 2025 at 07:12 AM UTC•By FilingReader AI
JCR Pharmaceuticals reported a net loss of 546 million yen for Q1 FY2025, compared with a 201 million yen profit in the prior year. Net sales rose 5.2% to 8.57 billion yen, but operating losses deepened to 606 million yen due to higher R&D expenses.
The company secured two major licensing deals: an agreement with Alexion worth up to $825 million for JUST-AAV capsids, and a collaboration with Acumen on Alzheimer's disease treatment worth up to $555 million.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
TSE:4552•Tokyo Stock Exchange
News Alerts
Get instant email alerts when Jcr Pharmaceuticals publishes news
Free account required • Unsubscribe anytime